# Surefire Infusion System vs. Standard Microcatheter Use During Holmium-166 Radioembolization

> **NCT02208804** · PHASE2,PHASE3 · UNKNOWN · sponsor: **UMC Utrecht** · enrollment: 25 (estimated)

## Conditions studied

- Colorectal Neoplasms
- Neoplasm Metastasis
- Liver Diseases
- Digestive System Neoplasms

## Interventions

- **DEVICE:** Holmium-166-poly (L-lactic acid) microspheres

## Key facts

- **NCT ID:** NCT02208804
- **Lead sponsor:** UMC Utrecht
- **Sponsor class:** OTHER
- **Phase:** PHASE2,PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2014-11
- **Primary completion:** 2017-11
- **Final completion:** —
- **Target enrollment:** 25 (ESTIMATED)
- **Last updated:** 2016-11-09


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02208804

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02208804, "Surefire Infusion System vs. Standard Microcatheter Use During Holmium-166 Radioembolization". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT02208804. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*